NCT00259831View on ClinicalTrials.gov

Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults

PHASE3CompletedINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

August 31, 2006

Conditions

Upper Respiratory Infection

Interventions

DRUG

CVT-E002 (Cold-FX); a natural health product

Trial Locations (1)

T5K 2J8

The Capital Care Group Continuing Care facilities, Edmonton

Sponsors

Lead Sponsor

CV Technologies

All Listed Sponsors

collaborator

Capital Health, Canada

OTHER

lead

CV Technologies

INDUSTRY

NCT00259831 - Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults | Biotech Hunter | Biotech Hunter